PAH Reddit Mentions | ChartExchange

**GOSS is the ticker for Gossamer Bio, Inc.** (Nasdaq: GOSS), a clinical-stage biopharmaceutical company based in San Diego, California.
# What the company does
It focuses on developing and commercializing **seralutinib** (also referred to as GB002), an inhaled small-molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways. The primary indications are:
* Pulmonary arterial hypertension (PAH)
* Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Seralutinib is in late-stage development (Phase 3 PROSERA trial completed). The company previously had a collaboration with Chiesi but recently reacquired worldwide rights. It is a pre-commercial biotech with ongoing losses and a history of capital raises and debt restructuring

What’s currently moving the stock
The main recent catalyst (late July 2026) was a positive regulatory and strategic update:
* After a Pre-NDA Type B meeting with the FDA, the company plans to submit a New Drug Application (NDA) for seralutinib in PAH in **September 2026**. The FDA treated certain statistical and treatment-effect issues from the PROSERA trial as review issues rather than filing barriers.
* Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi (Chiesi pays Gossamer $5 million; Gossamer owes future capped royalties and milestones).
* Stockholders approved a convertible note exchange that reduced debt principal by roughly $116 million and authorized a potential reverse stock split for Nasdaq compliance.
* Cash position was reported at approximately $57 million as of June 30, 2026
# Price predictions / analyst views
Analyst coverage is limited but leans constructive on the NDA path:
* Consensus rating is generally **Buy** / Outperform among covering firms.
* Average 12-month price targets across sources range roughly **$1.00–$3.86** (some individual targets as low as $0.28 and as high as $15). This implies substantial upside from recent prices in the $0.18–$0.21 area, though targets vary widely and often lag extreme price moves.
* Recent actions include Leerink upgrading to Outperform (target $1) after the FDA update, H.C. Wainwright reiterating Buy (target $2), and others maintaining Hold or more cautious views
**Short sellers of GOSS (Gossamer Bio) are primarily institutional traders, hedge funds, and market-making firms that report short (or put) positions via 13F filings and related disclosures.** Exact real-time individual short positions are not fully public (short interest is aggregated and reported twice monthly by Nasdaq/FINRA), but the most commonly cited institutions that have disclosed short or put exposure include:
* Alpine Global Management LLC
* Ikarian Capital LLC
* Tudor Investment Corp
* Caption Management LLC
* Boothbay Fund Management LLC
* ADAR1 Capital Management LLC
* DeepCurrents Investment Group LLC
* Jane Street Group LLC
* Group One Trading LLC
* Simplex Trading LLC
* Citadel Advisors, Susquehanna, and others (often via put)
IF YOU HAVE BETTER STOCK THIS ONE , PLEASE SHARE AND LETS SEE

MAY THE GODS BE WITH YOU